FDA
panel backs Amgen copy of
AbbVie arthritis drug Humira
(Reuters) -
Amgen Inc's cheaper version of AbbVie's top-selling
arthritis drug Humira is highly similar to the original and should be approved, an advisory
panel to the U.S. Food and
drug Administration concluded on Tuesday.
